Author

T. W. Corson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Cell Biology· 1 Pathology· 1 Scientific Communication & Education· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:mouse· 4 Research Focus:cell signaling & trafficking· 2 Research Focus:development & morphogenesis· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:proteomics· 2

Frequent Co-Authors

K. Sishtla· 3 shared B. Park· 2 shared T. Shetty· 2 shared A. Balaji· 1 shared A. Hinshaw· 1 shared A. Motolani· 1 shared A. Muniyandi· 1 shared D. White· 1 shared

Activity by Year

2018-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

K. Sishtla

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

PRMT5 is a therapeutic target in choroidal neovascularization

A. Muniyandi, M. Martin, M. Sun, K. Sishtla, N. R. Jensen, A. Motolani, X. Qi, M. E. Boulton, L. Prabhu, T. Lu, T. W. Corson

This study identifies PRMT5 as a therapeutic target for neovascular age-related macular degeneration by showing its inhibition reduces NF-κB activity and angiogenic properties in ocular endothelial cells.

bioRxiv · Mar 30, 2022Pharmacology & Toxicology

Building a virtual summer research experience in cancer for high school and early undergraduate students: lessons from the COVID-19 pandemic

T. W. Corson, S. M. Hawkins, E. Sanders, J. Byram, L.-A. Cruz, J. Olson, E. Speidell, R. Schnabel, A. Balaji, O. Ogbeide, J. Dinh, A. Hinshaw, L. Cummings, V. Bonds, H. Nakshatri

This paper describes a virtual summer research program in cancer for high school and early undergraduate students during the COVID-19 pandemic and evaluates its outcomes.

bioRxiv · Nov 23, 2020Scientific Communication & Education

Ferrochelatase regulates retinal neovascularization

S. P. S. Pran Babu, D. White, T. W. Corson

This paper shows that inhibiting ferrochelatase (FECH) reduces retinal neovascularization and promotes physiological angiogenesis in a mouse model, suggesting FECH inhibitors could treat retinal diseases.

bioRxiv · Jun 2, 2020Pathology

Heme synthesis inhibition blocks angiogenesis via mitochondrial dysfunction

T. Shetty, K. Sishtla, B. Park, M. J. Repass, T. W. Corson

This study shows that inhibiting heme synthesis disrupts mitochondrial function in endothelial cells, leading to impaired angiogenesis.

bioRxiv · Nov 9, 2019Cell Biology

Ref-1/APE1 inhibition with novel small molecules blocks ocular neovascularization

S. P. Sheik Pran Babu, K. Sishtla, R. S. Sulaiman, B. Park, T. Shetty, F. Shah, M. L. Fishel, J. H. Wikel, M. R. Kelley, T. W. Corson

This paper develops and tests new Ref-1/APE1 inhibitors, showing they block ocular neovascularization in vitro, ex vivo, and in a mouse model.

bioRxiv · Jun 23, 2018Pharmacology & Toxicology